

**Technology Advisory Committee B Interests Register**  
**ID3822 Burosumab for treating X-linked hypophosphataemia in adults**  
**Publication Date: 07/08/2024**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Oliver Gardener	Patient Expert	Direct – non-financial	<p>Feb 22 to Jan 23, XLH UK received 95% of its income from Kyowa Kirin</p> <p>Feb 22 to Jan 23, IXLHA received a restricted grant Kyowa Kirin, 71% of its income.</p> <p>Feb 23 to Jan 23, IXLHA received, £515 from Kyowa Kirin Australia as unrestricted donation.</p>	15/02/2024	N/A	It was agreed that Oliver's declaration would not prevent him from providing expert advice to the committee.
Margarita Vidal	Patient Expert	Direct – non-Financial	<p>Feb 22 to Jan 23, XLH UK received 95% of its income from Kyowa Kirin</p> <p>Feb 22 to Jan 23, IXLHA received a restricted grant Kyowa Kirin, 71% of its income.</p>	15/02/2024	NA	It was agreed that Margarita's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			Feb 23 to Jan 23, IXLHA received, £515 from Kyowa Kirin Australia as unrestricted donation.			
Kassim Javaid	Clinical Expert	Direct – non-financial	<p>Feb 22 to Jan 23, XLH UK received 95% of its income from Kyowa Kirin</p> <p>Feb 22 to Jan 23, IXLHA received a restricted grant Kyowa Kirin, 71% of its income.</p> <p>Feb 23 to Jan 23, IXLHA received, £515 from Kyowa Kirin Australia as unrestricted donation.</p>	15/02/2024	N/A	It was agreed that Kassim's declaration would not prevent him from providing expert advice to the committee.
Richard Keen	Clinical Expert	Direct – financial	Consultancy work for Kyowa Kirin in the field of XLH and its treatment Honorarium from Kyowa Kirin for lectures on XLH	15/02/2024	N/A	It was agreed that Richard's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Richard Keen	Clinical Expert	Direct – non-financial	Managing patients treated with Burosumab through an Early Access Programme funded by Kyowa Kirin Medical advisor and advocate for XLH-UK a patient charity.	15/02/2024	N/A	It was agreed that Richard's declaration would not prevent him from providing expert advice to the committee.
Dr Prithwiraj Das	TAC C Member	Non-Financial Professional	Prithwirjas works in life sciences, including pharmaceutical market access, as Founding Director of G2PR ltd. He has not worked on these products/indications in the last 12+ months.	15/02/2024	N/A	It was agreed that Prithwiraj's declaration would not prevent him from being on the committee.